Literature DB >> 26124820

Alpha thalassemia among sickle cell anaemia patients in Kampala, Uganda.

Irene Lubega1, Christopher M Ndugwa1, Edison A Mworozi1, James K Tumwine1.   

Abstract

BACKGROUND: Sickle cell anaemia is prevalent in sub Saharan Africa. While α+-thalassaemia is known to modulate sickle cell anaemia, its magnitude and significance in Uganda have hitherto not been described.
OBJECTIVES: To determine the prevalence of α+thalassaemia among sickle cell anaemia patients in Mulago Hospital and to describe the clinical and laboratory findings in these patients.
METHODS: A cross sectional study was carried out on patients with sickle cell anaemia in Kampala. Dried blood spots were used to analyze for the deletional α+ thalassaemia using multiplex polymerase chain reaction.
RESULTS: Of the 142 patients with sickle cell anaemia, 110 (77.5%) had the αα+thalassaemia deletion. The gene frequency of (-α) was 0.425. Ninety one percent (100/110) of those with α+thalassaemia were heterozygous (αα/α-). Amongst the patients older than 60 months, 15 (83.3%) of those without αα+thalassaemia had significant hepatomegaly of greater than 4 cm compared to 36 (45.6%) of those with α+thalassaemia (p=0.003).
CONCLUSION: The gene frequency of (-α) of 0.425 noted in this study is higher than that reported from many places in Africa. Concurrent alpha thalassemia might be a protective trait against significant hepatomegaly in sickle cell anaemia patients more than 60 months of age at Mulago hospital.

Entities:  

Keywords:  Alpha thalassemia; Kampala; Uganda; sickle cell anaemia patients

Mesh:

Year:  2015        PMID: 26124820      PMCID: PMC4480462          DOI: 10.4314/ahs.v15i2.48

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  43 in total

1.  Homozygous sickle cell disease in Uganda and Jamaica a comparison of Bantu and Benin haplotypes.

Authors:  C Ndugwa; D Higgs; C Fisher; I Hambleton; K Mason; B E Serjeant; G R Serjeant
Journal:  West Indian Med J       Date:  2012-10       Impact factor: 0.171

2.  alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia.

Authors:  A M Dozy; Y W Kan; S H Embury; W C Mentzer; W C Wang; B Lubin; J R Davis; H M Koenig
Journal:  Nature       Date:  1979-08-16       Impact factor: 49.962

3.  Analysis of patients attending sickle cell anaemia clinic, New Mulago Hospital, 1970-1971.

Authors:  C M Ndugwa; F B Kanyike
Journal:  East Afr Med J       Date:  1973-04

4.  Benign obstetric history in women with sickle-cell anaemia associated with -thalassaemia.

Authors:  A van Enk; A Lang; J M White; H Lehmann
Journal:  Br Med J       Date:  1972-12-02

5.  Hemoglobin Bart's in Northern Algeria.

Authors:  T Henni; D Bachir; P Tabone; P Jurdic; J Godet; P Colonna
Journal:  Acta Haematol       Date:  1981       Impact factor: 2.195

6.  alpha-Thalassemia reduces the hemolytic rate in homozygous sickle-cell disease.

Authors:  K de Ceulaer; D R Higgs; D J Weatherall; R J Hayes; B E Serjeant; G R Serjeant
Journal:  N Engl J Med       Date:  1983-07-21       Impact factor: 91.245

7.  alpha thalassemia in black populations.

Authors:  D R Higgs; L Pressley; J B Clegg; D J Weatherall; G R Serjeant
Journal:  Johns Hopkins Med J       Date:  1980-06

8.  The association of sickle cell anemia with heterozygous and homozygous alpha-thalassemia-2: in vitro HB chain synthesis.

Authors:  A E Felice; B Webber; A Miller; S M Mayson; H F Harris; J B Henson; M E Gravely; T H Huisman
Journal:  Am J Hematol       Date:  1979       Impact factor: 10.047

9.  The interaction of alpha-thalassemia and homozygous sickle-cell disease.

Authors:  D R Higgs; B E Aldridge; J Lamb; J B Clegg; D J Weatherall; R J Hayes; Y Grandison; Y Lowrie; K P Mason; B E Serjeant; G R Serjeant
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

10.  Sickle cell syndromes. II. The sickle cell anemia-alpha-thalassemia syndrome.

Authors:  G R Honig; M Koshy; R G Mason; L N Vida
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

View more
  7 in total

1.  Infectious diseases and chronic care in Africa.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

2.  Association between sickle cell anemia and alpha thalassemia reveals a high prevalence of the α3.7 triplication in congolese patients than in worldwide series.

Authors:  Tite Minga Mikobi; Prosper Tshilobo Lukusa; Michel Ntetani Aloni; Aimé Lumaka; Pierre Zalagile Akilimali; Koenraad Devriendt; Gert Matthijs; Jean-Marie Mbuyi Muamba; Valerie Race
Journal:  J Clin Lab Anal       Date:  2017-03-09       Impact factor: 2.352

3.  Sickle-cell and alpha-thalassemia traits resulting in non-atherosclerotic myocardial infarction: Beyond coincidence?

Authors:  Lee S Nguyen; Alban Redheuil; Olivier Mangin; Joe-Elie Salem
Journal:  World J Clin Cases       Date:  2017-12-16       Impact factor: 1.337

4.  Influence of alpha thalassemia on clinical and laboratory parameters among nigerian children with sickle cell anemia.

Authors:  Oladele S Olatunya; Dulcineia M Albuquerque; Adekunle Adekile; Fernando F Costa
Journal:  J Clin Lab Anal       Date:  2018-08-20       Impact factor: 2.352

5.  Factors Associated with Growth Retardation in Children Suffering from Sickle Cell Anemia: First Report from Central Africa.

Authors:  Aimé Lukusa Kazadi; René Makuala Ngiyulu; Jean Lambert Gini-Ehungu; Jean Marie Mbuyi-Muamba; Michel Ntetani Aloni
Journal:  Anemia       Date:  2017-01-30

6.  A retinopathy in young patient with co-inheritance of heterozygous alpha + -thalassemia and sickle trait: a case report.

Authors:  Zohra Ouzzif; Aissam El Maataoui; Zeinab Traore; Asmae Biaz; Samira El Machtani; Abdellah Dami; Sanae Bouhsain; Nezha Messaoudi; Fatiha Benchrifa
Journal:  BMC Ophthalmol       Date:  2017-01-18       Impact factor: 2.209

7.  Beta Thalassemia Major with Gaucher's Disease: A Rare Entity.

Authors:  Naila Bai; Sharmeen Nasir; Jawad Ahmed; Farheen Malik; Taha Bin Arif
Journal:  Cureus       Date:  2019-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.